Oral Mucositis - Pipeline Review, H1 2018

  • ID: 4464918
  • Drug Pipelines
  • 96 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Clevexel Pharma SAS
  • Colby Pharmaceutical Co
  • Galera Therapeutics Inc
  • Humanetics Corp
  • Monopar Therapeutics LLC
  • Oragenics Inc
  • MORE
Oral Mucositis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis - Pipeline Review, H1 2018, provides an overview of the Oral Mucositis (Gastrointestinal) pipeline landscape.

Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the integrity of the mucosa and the presence of edema on the lips and/or the tongue. Treatment included oral decontamination (mouth care) and oral debridement.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Oral Mucositis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Oral Mucositis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oral Mucositis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 8, 3 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Oral Mucositis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Oral Mucositis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Oral Mucositis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Oral Mucositis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Oral Mucositis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Oral Mucositis (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Oral Mucositis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Oral Mucositis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Clevexel Pharma SAS
  • Colby Pharmaceutical Co
  • Galera Therapeutics Inc
  • Humanetics Corp
  • Monopar Therapeutics LLC
  • Oragenics Inc
  • MORE
Introduction

The Publisher's Report Coverage

Oral Mucositis - Overview

Oral Mucositis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Oral Mucositis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Oral Mucositis - Companies Involved in Therapeutics Development

Clevexel Pharma SAS

Colby Pharmaceutical Co

Galera Therapeutics Inc

Humanetics Corp

Innovation Pharmaceuticals Inc

Monopar Therapeutics LLC

Oragenics Inc

Soligenix Inc

Spectrum Pharmaceuticals Inc

Spherium Biomed SL

Oral Mucositis - Drug Profiles

AG-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avasopasem manganese - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCD-600 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIO-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brilacidin tetrahydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

clonidine hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVXL-0095 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dusquetide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-18 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Oral Mucositis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate SOD2 for Oral Mucositis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-0111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HYLP-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melatonin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

phenylbutyrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pralatrexate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize KGFR for Chemotherapy Induced Gastrointestinal Mucositis and Oral Mucositis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oral Mucositis - Dormant Projects

Oral Mucositis - Discontinued Products

Oral Mucositis - Product Development Milestones

Featured News & Press Releases

Jan 29, 2018: Innovation Pharmaceuticals Brilacidin Franchise Anchored in Three Clinical Indications — Oral Mucositis, Inflammatory Bowel Disease and Serious Skin Infections; Expands into Dermatologic Diseases

Jan 16, 2018: Innovation Pharmaceuticals Presents at 2018 Biotech Conference; Oral Mucositis Drug Candidate Garners Exceptional Interest After Successful Phase 2 Trial

Jan 04, 2018: Data from Galera Therapeutics' 223-Patient Phase 2b Clinical Trial of GC4419 to be Presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium

Jan 03, 2018: Innovation Pharmaceuticals Brilacidin Meets Key Secondary Endpoint in Phase 2 Trial, Delays Onset of Severe Oral Mucositis (SOM)

Jan 02, 2018: Soligenix Announces US Patent Issuance for Use of Dusquetide in Oral Mucositis

Dec 18, 2017: Galera Therapeutics Reports Statistically Significant Results in a 223-Patient Phase 2b Trial of GC4419 for Severe Oral Mucositis in Patients with Head and Neck Cancer

Dec 18, 2017: Innovation Pharmaceuticals Brilacidin Oral Mucositis Program Moving Forward Based Upon Positive Anchoring Phase 2 Results and Increased Brilacidin Franchise Value

Dec 12, 2017: Innovation Pharmaceuticals Granted European Patent for Brilacidin in the Prevention of Oral Mucositis

Dec 11, 2017: Innovation Pharmaceuticals Reports Positive Topline Results from Phase II Placebo-Controlled Trial of Brilacidin for the Prevention of Oral Mucositis in Head and Neck Cancer Patients

Nov 16, 2017: Innovation Pharmaceuticals Offers Perspectives on Brilacidin as a Potential Preventative Treatment for Oral Mucositis in Head and Neck Cancer Patients

Nov 09, 2017: Soligenix to Present Data on Dusquetide in Combating Antibiotic-Resistant Infections at the 2nd Annual Superbugs & Superdrugs USA Conference

Oct 26, 2017: Innovation Pharmaceuticals Aims to Develop First Drug for Approval in Prevention of Oral Mucositis in Head and Neck Cancer Patients as Phase 2 Clinical Trial of Brilacidin Completes

Oct 24, 2017: Broad-Spectrum Innate Defense Regulator Platform Technology to be Presented at the Peptide Therapeutics Foundation Symposium

Oct 18, 2017: Innovation Pharmaceuticals to Complete Phase 2 Trial of Brilacidin for Oral Mucositis in Cancer Patients

Oct 05, 2017: Dusquetide Technology Platform to be Presented at the 2nd World Congress and Expo on Immunology

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Oral Mucositis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Oral Mucositis - Pipeline by Clevexel Pharma SAS, H1 2018

Oral Mucositis - Pipeline by Colby Pharmaceutical Co, H1 2018

Oral Mucositis - Pipeline by Galera Therapeutics Inc, H1 2018

Oral Mucositis - Pipeline by Humanetics Corp, H1 2018

Oral Mucositis - Pipeline by Innovation Pharmaceuticals Inc, H1 2018

Oral Mucositis - Pipeline by Monopar Therapeutics LLC, H1 2018

Oral Mucositis - Pipeline by Oragenics Inc, H1 2018

Oral Mucositis - Pipeline by Soligenix Inc, H1 2018

Oral Mucositis - Pipeline by Spectrum Pharmaceuticals Inc, H1 2018

Oral Mucositis - Pipeline by Spherium Biomed SL, H1 2018

Oral Mucositis - Dormant Projects, H1 2018

Oral Mucositis - Dormant Projects, H1 2018 (Contd..1), H1 2018

Oral Mucositis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Oral Mucositis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Clevexel Pharma SAS
  • Colby Pharmaceutical Co
  • Galera Therapeutics Inc
  • Humanetics Corp
  • Innovation Pharmaceuticals Inc
  • Monopar Therapeutics LLC
  • Oragenics Inc
  • Soligenix Inc
  • Spectrum Pharmaceuticals Inc
  • Spherium Biomed SL
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll